The Madras High Court has directed the Indian Patent Office to reconsider a patent application filed by Skillz Platform Inc. after the company withdrew a method claim and retained a system claim, ruling that the application warranted fresh consideration in light of the amended claims.
In its November 11 decision in Skillz Platform Inc. v. Assistant Controller of Patents and Designs, the court remitted the application to a different Patent Controller for reconsideration, with the examination restricted to the system claim.
The decision highlights the procedural significance of claim amendments during patent prosecution and the importance of assessing patent applications in light of the claims ultimately pursued by an applicant.
Dispute over patentability of Skillz’s platform
Skillz Platform Inc. challenged the rejection of its patent application by the Indian Patent Office, arguing that the system and method claims had been examined together and that withdrawing the method claim could affect the assessment of the system claim it continued to pursue.
The Patent Controller opposed the remand, maintaining that the rejection order contained detailed findings on the claims and had considered the exclusions under Sections 3(k) and 3(m) of India’s Patents Act, 1970.
Section 3(k) excludes computer programs per se and algorithms from patentability, while Section 3(m) addresses methods of performing mental acts and methods of playing games. These statutory exclusions formed part of the underlying patentability dispute.
The court considered that withdrawing the method claim while retaining the system claim could affect the Controller’s conclusion on whether the application warranted a patent grant. It therefore concluded that the application should be reconsidered in light of the amended claims, rather than relying solely on the earlier assessment.
Fresh examination by a different Controller
The Madras High Court directed that the application be reconsidered afresh by a different Patent Controller, with the examination limited to the system claim alone.
The court also directed the Patent Office to complete its reconsideration within four months of receiving the order. If necessary, the Controller may seek the opinion of a scientific adviser, including a professor from IIT Madras, with the respondent bearing the remuneration.
The remand does not amount to a finding that the invention is patentable. Instead, the application must undergo fresh consideration on the basis of the claim that remains under consideration, with the relevant statutory exclusions still to be assessed.
Implications for patent examination in India
The decision reinforces the procedural importance of claim amendments in patent prosecution and the need for examination decisions to reflect the claims an applicant ultimately seeks to protect.
For patent applicants, withdrawing or narrowing claims may materially alter the issues requiring consideration by the Patent Office. Where the claims pursued differ from those assessed in the rejection, the decision illustrates the potential for judicial review to require a fresh examination of the application.
However, the ruling does not establish that withdrawing a method claim automatically overcomes objections under Sections 3(k) or 3(m). Patentability remains dependent on the substance of the remaining claim and the applicable statutory requirements.
The decision provides a further example of the Madras High Court’s role in reviewing patent examination decisions and directing reconsideration where changes to the claims warrant a fresh assessment.

Written by Elizabeth Jordan
Senior Industry Engagement Manager, CTC Legal Media
You may also like…
BIP Asia Forum and Entrepreneur Day open today
Advancing innovation and global expansion November 19, 2026 – The 16th Business of IP Asia Forum (BIP Asia Forum),...
UPC confronts alleged abuse of divisional patent applications in Sandoz v. Novo Nordisk
The Unified Patent Court (UPC) has confirmed that it can take measures to prevent patent proprietors from using...
GSK wins major UPC patent ruling against Pfizer and BioNTech over mRNA vaccine technology
The Unified Patent Court has found that Pfizer and BioNTech infringed GSK's patent covering lipid-based RNA delivery...
Contact us to write for out Newsletter











